Have a personal or library account? Click to login
Baseline and dynamic changes in skeletal muscle mass as predictive biomarkers in patients with metastatic renal cell carcinoma treated with Nivolumab Cover

Baseline and dynamic changes in skeletal muscle mass as predictive biomarkers in patients with metastatic renal cell carcinoma treated with Nivolumab

Radiology and Oncology
Volume 59 (2025): Issue 4 (December 2025)
By: Erdem Ozkan,  Murathan Koksal,  Bunyamin Ece,  Mustafa Koyun,  Omer Faruk Kuzu,  Yusuf Acikgoz and  Efnan Algin  
Open Access
|Dec 2025

References

  1. Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol 2019; 75: 74-8. doi: 10.1016/j.eururo.2018.08.036
    Open DOISearch in Google ScholarBack to article
  2. Ferlay J, Ervik M, Lam, F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; 2020.
    Search in Google ScholarBack to article
  3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-63. doi: 10.3322/caac.21834
    Open DOISearch in Google ScholarBack to article
  4. Mathers CD. History of global burden of disease assessment at the World Health Organization. Arch Public Health 2020: 24; 78-87. doi: 10.1186/s13690-020-00458-3
    Open DOISearch in Google ScholarBack to article
  5. Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Exp Med 2025; 25: 238. doi: 10.1007/s10238-025-01751-7
    Open DOISearch in Google ScholarBack to article
  6. Venur VA, Joshi M, Nepple KG, Zakharia Y. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther 2017: 11: 1175-82. doi: 10.2147/DDDT.S110209
    Open DOISearch in Google ScholarBack to article
  7. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Writing group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31. doi: 10.1093/ageing/afy169
    Open DOISearch in Google ScholarBack to article
  8. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Costello BA, Thompson RH, et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol 2016; 195: 270-6. doi: 10.1016/j.juro.2015.08.072
    Open DOISearch in Google ScholarBack to article
  9. Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol 2015; 33: 339. e17-23. doi: 10.1016/j.urolonc.2015.01.011
    Open DOISearch in Google ScholarBack to article
  10. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol 2016; 195: 26-32. doi: 10.1016/j.juro.2015.08.071
    Open DOISearch in Google ScholarBack to article
  11. Nikodinovska V, Ivanoski S. Sarcopenia, more than just muscle atrophy: imaging methods for the assessment of muscle quantity and quality. Rofo 2023; 195: 777-89. doi: 10.1055/a-2057-0205.
    Open DOISearch in Google ScholarBack to article
  12. Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition 2019; 67-68: 110539. doi: 10.1016/j.nut.2019.06.020
    Open DOISearch in Google ScholarBack to article
  13. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18: e143-52. doi: 10.1016/S1470-2045(17)30074
    Open DOISearch in Google ScholarBack to article
  14. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 2014; 210: 489-97. doi: 10.1111/apha.12224
    Open DOISearch in Google ScholarBack to article
  15. Ryan AM, Power DG, Daly L, Cushen SJ, Ní Bhuachalla Ē, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016; 75: 199-211. doi: 10.1017/S002966511500419X
    Open DOISearch in Google ScholarBack to article
  16. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008; 33: 997-1006. doi: 10.1139/H08-075
    Open DOISearch in Google ScholarBack to article
  17. Lee J, Suh J, Song C, You D, Jeong IG, Hong B; et al. Association between sarcopenia and survival of patients with organ-confined renal cell carcinoma after radical nephrectomy. Ann Surg Oncol 2022; 29: 2473-9. doi: 10.1245/s10434-021-10881-7
    Open DOISearch in Google ScholarBack to article
  18. Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care 2009; 3: 269-75. doi: 10.1097/SPC.0b013e328331124a.
    Open DOISearch in Google ScholarBack to article
  19. Hu X, Liao DW, Yang ZQ, Yang WX, Xiong SC, Li X. Sarcopenia predicts prognosis of patients with renal cell carcinoma: a systematic review and meta-analysis. Int J Brauz Urol 2020; 46: 705-15. doi. 10.1590/S1677-5538. IBJU.2019.0636
    Open DOISearch in Google ScholarBack to article
  20. Herrmann T, Mione C, Montoriol PF, Molnar I, Ginzac A, Durando X, et al. Body mass index, sarcopenia, and their variations in predicting outcomes for patients treated with nivolumab for metastatic renal cell carcinoma. Oncology 2022; 100: 114-23. doi: 10.1159/000520833
    Open DOISearch in Google ScholarBack to article
  21. Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol 2015; 33: 339. e17-23. doi: 10.1016/j.urolonc.2015.01.011
    Open DOISearch in Google ScholarBack to article
  22. Ueki H, Hara T, Okamura Y, Bando Y, Terakawa T, Furukawa J, et al. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: a retrospective study. Investig Clin Urol 2022; 63: 415-24. doi: 10.4111/icu.20220028
    Open DOISearch in Google ScholarBack to article
  23. Ishihara H, Takagi T, Kondo T, Fukuda H, Yoshida K, Iizuka J et al. Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma. Target Oncol 2018; 13: 745-55. doi: 10.1007/s11523-018-0600-3
    Open DOISearch in Google ScholarBack to article
  24. Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: the emerging roles of myokines. Endocr Rev 2020; 41: 594-609. doi: 10.1210/endrev/bnaa016
    Open DOISearch in Google ScholarBack to article
  25. Deng Y, Zhao L, Huang X, Zeng Y, Xiong Z, Zuo M. Contribution of skeletal muscle to cancer immunotherapy: a focus on muscle function, inflammation, and microbiota. Nutrition 2023; 105: 111829. doi: 10.1016/j. nut.2022.111829
    Open DOISearch in Google ScholarBack to article
  26. Li S, Wang T, Tong G, Li X, You D, Cong M. Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol 2021; 11: 726257. doi: 10.3389/fonc.2021.726257
    Open DOISearch in Google ScholarBack to article
  27. Bilen MA, Martini DJ, Liu Y, Shabto JM, Brown JT, Williams M, et al. Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy. Oncologist 2020; 25: e528-35. doi: 10.1634/theoncologist.2019-0751
    Open DOISearch in Google ScholarBack to article
  28. McKinnon MB, Rini BI, Haake SM. Biomarker-informed care for patients with renal cell carcinoma. Nat Cancer 2025; 6: 573-83. doi: 10.1038/s43018-025-00942-1
    Open DOISearch in Google ScholarBack to article
  29. Sahin TK, Guven DC. Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin Nutr ESPEN 2024; 63: 829-36. doi: 10.1016/j.clnesp.2024.08.015
    Open DOISearch in Google ScholarBack to article
  30. Ahn H, Kim DW, Ko Y, Ha J, Shin YB, Lee J, et al. Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia. Ageing Res Rev 2021; 70: 101398. doi: 10.1016/j.arr.2021.101398
    Open DOISearch in Google ScholarBack to article
DOI: https://doi.org/10.2478/raon-2025-0065 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 624 - 634
Submitted on: Jun 25, 2025
Accepted on: Oct 20, 2025
Published on: Dec 16, 2025
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
renal cell carcinoma,
low muscle mass,
computed tomography,
nivolumab
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology,
Radiology

© 2025 Erdem Ozkan, Murathan Koksal, Bunyamin Ece, Mustafa Koyun, Omer Faruk Kuzu, Yusuf Acikgoz, Efnan Algin, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 59 (2025): Issue 4 (December 2025)